Trial Profile
A Phase 2 Study of Docetaxel and Carboplatin for Treatment of Patients With Metastatic, Castration Resistant Prostate Cancer and Germline or Somatic DNA Repair Deficiency
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Docetaxel (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 03 Aug 2021 Status changed from recruiting to discontinued.
- 16 Feb 2019 Results of Veterans health administration precision oncology program presented at the 2019 Genitourinary Cancers Symposium.
- 06 Dec 2018 Planned End Date changed from 1 Dec 2022 to 1 Dec 2024.